CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Antiepileptic, hydantoin derivative (sodium channel blocker)
Updated · Methodology
Mechanism
Phenytoin is a potent inducer of the liver enzymes that metabolise drugs and can lower the levels of drugs that these enzymes clear (phenytoin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The cobicistat SmPC and label class phenytoin as a strong CYP3A inducer, and CYP3A metabolises both cobicistat and the atazanavir or darunavir it boosts (cobicistat SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). The levels of cobicistat and of the boosted drug fall, and human immunodeficiency virus (HIV) treatment may lose its effect, with a risk of drug resistance (cobicistat SmPC, EMA). The documents do not describe any effect of cobicistat on phenytoin. CYP2C9 and CYP2C19 clear phenytoin (phenytoin SmPC, AEMPS), and the cobicistat SmPC does not expect cobicistat to inhibit CYP2C9 or CYP2C19 (cobicistat SmPC, EMA).
Symptoms
The fall in the levels of cobicistat and of the boosted drug causes no symptoms by itself. The main risk is that the antiviral regimen loses its effect and human immunodeficiency virus (HIV) becomes resistant to the drugs (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). Laboratory tests, not how the person feels, show a loss of virologic response (cobicistat FDA label).
Management
The combination is contraindicated. Phenytoin is on the cobicistat contraindication list together with carbamazepine and phenobarbital. As strong CYP3A inducers, they lower the levels of cobicistat and of the drug it boosts, and treatment may lose its effect (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). The same contraindication appears in the SmPCs of the combination tablets of cobicistat with darunavir, atazanavir and elvitegravir (SmPCs of these products, EMA). The phenytoin SmPC does not name cobicistat, but it lists several antiretroviral drugs, including ritonavir, indinavir and lopinavir/ritonavir, among the drugs whose levels and effects phenytoin can change (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For a person taking cobicistat, choose seizure treatment without phenytoin, carbamazepine or phenobarbital (cobicistat SmPC, EMA, and FDA label). No document gives an interval between stopping phenytoin and starting cobicistat. Oxcarbazepine and eslicarbazepine also induce CYP3A but are not contraindicated. With them, consider an alternative anticonvulsant or antiretroviral drug, and if the combination is necessary, monitor for loss of virologic response (cobicistat FDA label). Before starting cobicistat and during treatment, consider possible interactions, review all concomitant medicines and monitor for their adverse effects (cobicistat FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Fenitoína (nº registro 45695), secciones 4.3 y 4.5 (2024)– AEMPS, CIMA, Epanutin 100 mg cápsulas duras, nº registro 45695, revisión 01/2024, secciones 4.3 y 4.5
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- EMA: Ficha técnica: Cobicistat, Tybost (EU/1/13/872), sección 4.3 (2026)– EMA, Tybost 150 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida, Genvoya (EU/1/15/1061), sección 4.3 (2026)– EMA, Genvoya 150 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151061001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5